Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Final submission from Genentech focuses on revised indication and Risk Evaluation and Mitigation Strategy to support continued approval while it conducts another confirmatory trial.

You may also be interested in...



Perjeta, Avastin Breast Cancer Approvals Are A Study In Contrasts

Pertuzumab’s approval came almost a year after FDA and Genentech battled over the future of bevacizumab’s breast cancer claim at an unprecedented public hearing. While both oncologic agents were approved on the basis of a median progression-free survival benefit exceeding five months, the regulatory similarities end there.

Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP

Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.

Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP

Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel